Dr. Barratt’s research is focussed on a bench to bedside approach to improving our understanding of the pathogenesis of IgA nephropathy a common global cause of kidney failure. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and Convener of the International IgA Nephropathy Network. He works closely with pharmaceutical companies interested in new treatments for IgA nephropathy, and is Chief Investigator for a number of international randomised controlled Phase 2 and 3 clinical trials in IgA nephropathy. He is co-Chair of the UK Glomerulonephritis Clinical Study Group and the IgA nephropathy lead for the KDIGO Clinical Practice Guidelines for Glomerular Diseases.
讲座视频:0
论文摘要:3
102
0
0
日期 | 时间 | 会场 | Session | 角色 | 讲题 |
---|---|---|---|---|---|
2024-10-16 | 09:20-09:50 | 第一会场:智悦厅 |
Session 2: The Nephrosis |
讲者 | Membranous Nephropathy |
2024-10-17 | 08:30-09:00 | 第一会场:智悦厅 |
Session 7: The Hematonephrologist |
讲者 | Amyloidosis, Fibrillary & Immunotactoid GN |
2024-10-18 | 10:10-10:40 | 第一会场:智悦厅 |
ISN-CSN Joint Session 1 |
讲者 | Where do the new IgAN KDIGO Guidelines take us in the care of patients with IgAN? |